Articles

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Laboratory of Hematology, University Hospital of Bordeaux, Hôpital Haut Lévêque, Pessac, France; Groupe Fi-LMC, Centre Léon Bérard, Lyon, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; INSERM U1052, Centre de Recherche de Cancérologie de Lyon, Centre Léon Bérard, Lyon, France; Hematology department, Centre Léon Bérard, Lyon, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Adult Hematology Department, Hôpital Saint Louis, Paris, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department and Clinical Investigation Center, Centre Hospitalier Annecy-Genevois, Metz-Tessy, Pringy, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Institut Paoli-Calmettes, Marseilles, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHU de Pontchaillou, Rennes, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHU Huriez, Lille, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Institut Henri Becquerel, Rouen, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Institut Universitaire du Cancer, CHU de Toulouse, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology and Oncology department, Centre Hospitalier de Valence, Valence, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHRU Brabois, Nancy, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Morvan Hospital, CHU, Brest, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHU, Angers, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHU Dupuytren, Limoges, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Hôtel Dieu, Nantes, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Centre Hospitalier de Versailles, Le Chesnay, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Centre Hospitalier de Saint Brieuc, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Centre Hospitalier de Bretagne, Vannes, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Institute of Normandy, CHU de la Côte de Nacre, Caën, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CH Sud francilien, Corbeil-Essonne, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHR La Réunion, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, CHU de Poitiers, Poitiers, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Centre Hospitalier, Saint Pierre de La Réunion, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology (Biology) department, CHU Estaing, Clermont-Ferrand, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Internal medicine and onco-hematology department, La Roche sur Yon, France
Laboratory of Hematology, University Hospital of Bordeaux, Hôpital Haut Lévêque, Pessac, France
INSERM U1052, Centre de Recherche de Cancérologie de Lyon, Centre Léon Bérard, Lyon, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Institut Bergonié, Bordeaux, France
Groupe Fi-LMC, Centre Léon Bérard, Lyon, France; Hematology department, Institut Bergonié, Bordeaux, France
Haematologica Early view May 26, 2022 https://doi.org/10.3324/haematol.2022.280811